TREATMENT WITH ŒSTROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Ethinylœstradiol was administered to 10 post-menopausal hyperparathyroid patients. There was a gradual fall in the fasting plasma-calcium and urine-calcium and in the 24-hour- urine calcium and hydroxyproline, which was maintained up to one year in the patients who continued therapy. Œstrogen treatment of hyperparathyroidism in post-menopausal women might be expected to prevent bone disease by inhibiting bone resorption, and stone disease by reducing urine-calcium.

Original languageEnglish
Pages (from-to)503-507
Number of pages5
JournalThe Lancet
Volume299
Issue number7749
DOIs
StatePublished - Mar 4 1972
Externally publishedYes

Fingerprint

Primary Hyperparathyroidism
Calcium
Urine
Hyperparathyroidism
Bone Diseases
Hydroxyproline
Therapeutics
Bone Resorption
Fasting
IDS 89 Sabal serrulata extract

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

TREATMENT WITH ŒSTROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN. / Gallagher, John Christopher G.; Nordin, B. E C.

In: The Lancet, Vol. 299, No. 7749, 04.03.1972, p. 503-507.

Research output: Contribution to journalArticle

@article{e6ddf206feb843c78119c1ab9b7739c6,
title = "TREATMENT WITH ŒSTROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN",
abstract = "Ethinylœstradiol was administered to 10 post-menopausal hyperparathyroid patients. There was a gradual fall in the fasting plasma-calcium and urine-calcium and in the 24-hour- urine calcium and hydroxyproline, which was maintained up to one year in the patients who continued therapy. Œstrogen treatment of hyperparathyroidism in post-menopausal women might be expected to prevent bone disease by inhibiting bone resorption, and stone disease by reducing urine-calcium.",
author = "Gallagher, {John Christopher G.} and Nordin, {B. E C}",
year = "1972",
month = "3",
day = "4",
doi = "10.1016/S0140-6736(72)90173-0",
language = "English",
volume = "299",
pages = "503--507",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "7749",

}

TY - JOUR

T1 - TREATMENT WITH ŒSTROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN

AU - Gallagher, John Christopher G.

AU - Nordin, B. E C

PY - 1972/3/4

Y1 - 1972/3/4

N2 - Ethinylœstradiol was administered to 10 post-menopausal hyperparathyroid patients. There was a gradual fall in the fasting plasma-calcium and urine-calcium and in the 24-hour- urine calcium and hydroxyproline, which was maintained up to one year in the patients who continued therapy. Œstrogen treatment of hyperparathyroidism in post-menopausal women might be expected to prevent bone disease by inhibiting bone resorption, and stone disease by reducing urine-calcium.

AB - Ethinylœstradiol was administered to 10 post-menopausal hyperparathyroid patients. There was a gradual fall in the fasting plasma-calcium and urine-calcium and in the 24-hour- urine calcium and hydroxyproline, which was maintained up to one year in the patients who continued therapy. Œstrogen treatment of hyperparathyroidism in post-menopausal women might be expected to prevent bone disease by inhibiting bone resorption, and stone disease by reducing urine-calcium.

UR - http://www.scopus.com/inward/record.url?scp=0015493551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015493551&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(72)90173-0

DO - 10.1016/S0140-6736(72)90173-0

M3 - Article

VL - 299

SP - 503

EP - 507

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7749

ER -